This “Active Pharmaceutical Ingredients (API) Market” report 2019-2024 provides an in-depth analysis of the current trends and future approximations to represent the forthcoming investment plans. The Active Pharmaceutical Ingredients (API) market report presents the vendor landscape and consistent detailed analysis of the major vendors operating in the market. The report provides a competitive environment of the Active Pharmaceutical Ingredients (API) market is based on company profiles and their efforts on increasing product value and production.
The Report Covers:
- Comprehensive research methodology of Active Pharmaceutical Ingredients (API) market
- In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Active Pharmaceutical Ingredients (API) market
- Insights about market determinants which are inspiring the Active Pharmaceutical Ingredients (API) market
- Detailed and extensive market segments with regional distribution of forecasted revenues
- Extensive profiles and recent developments of market players Companies Mentioned
For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/14245757
Key Questions Answered in This Report:
- What are the market dynamics?
- What are the key market trends?
- What are the category growth drivers?
- What are the constraints on category growth?
- Who are the suppliers in this market?
- What are the demand-supply shifts?
- What are the major category requirements?
Key Market Trends:
Cardiology is Expected to hold the Largest Market Share in the Application Category
The API market, by application, is dominated by the cardiology segment, due to the vast population using various CVD drugs. This segment is projected to witness a CAGR of 6.05% during the forecast period.
Coronary heart disease (CHD) is the most common type of cardiac disease, with a death toll of over 370,000 people, annually, in the United States alone. According to the American Heart Association (AHA), cardiovascular disease accounts for 17.3 million deaths per year. The Centre for Disease Control and Prevention states that about 610,000 people die of heart diseases in the United States every year, i.e., one in every four deaths can be attributed to cardiovascular diseases (CVDs).
Cholesterol reducers and blood pressure lowering drugs are the key drug classes under CVS. Cholesterol reducers, especially Statins, are driving the CVS segment, and have emerged as the most important family of drugs among the cholesterol and triglycerides reducers. Healthcare spending for hypertension was USD 23 to 26 billion in 2017, in the developed markets alone. Another USD 14 to 17 billion was spent in 2017 in the pharmerging markets. The high expenditure on the cardiovascular category highlights the rising demand for APIs in the same.
North America Dominates the Market and is expected to continue its dominance through the Forecast Period
North America currently dominates the market for active pharmaceutical ingredients and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increasing incidences of disease and rising aging population. The United States holds the majority of the market in the North American region. However, the majority of its API requirements are met through imports from the Asian Markets. The trade statistics suggest that nearly 75% to 80% of the APIs imported to the United States are from China and India, as these countries have well-established manufacturing facilities and an abundant talent pool serving the pharmaceutical sector.
The recent political and trade policies implemented by the US government to increase import duties and taxes are expected to drive operational costs and increase the pricing pressure on the manufacturers. The FDA has also increased the application fees for new drug approvals and has increased the number of periodic inspections conducted on various off-share contract manufacturing facilities to ensure the supply of high-quality products to the US market.
Purchase this Report (Price 4250 USD for single user license) – https://www.industryresearch.co/purchase/14245757
Detailed TOC of Active Pharmaceutical Ingredients (API) Market 2019-2024:
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Infectious, Genetic, Cardiovascular, and Other Chronic Disorders
4.2.2 Increasing Adoption of Biologicals and Biosimilars
4.2.3 Rising Prevalence of Cancer and Increasing Sophistication in Oncology Drug Research
4.3 Market Restraints
4.3.1 Drug Price Control Policies Across Various Countries
4.3.2 High Competition Between the API Manufacturers
4.3.3 Stringent Regulations
4.4 Industry Attractiveness Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Business Mode
5.1.1 Captive API
5.1.2 Merchant API
5.2 By Synthesis Type
5.3 By Type
5.4 By Application
5.4.7 Other Applications
5.5.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.5.4 Middle East & Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle East & Africa
5.5.5 South America
126.96.36.199 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Aurobindo Pharma
6.1.2 Teva Pharmaceutical Industries Ltd
6.1.3 Pfizer Inc.
6.1.4 Novartis AG
6.1.5 BASF SE
6.1.6 Boehringer Ingelheim GmbH
6.1.7 Dr. Reddy’s Laboratories Ltd
6.1.8 Lupin Ltd
6.1.9 Mylan NV
6.1.10 Sun Pharmaceutical Industries Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Name: Ajay More
Phone: US +14242530807/ UK +44 20 3239 8187
Email: [email protected]
Our Other Reports: